文献速递胸部肿瘤放疗

非小细胞肺癌同步放化疗后立体定向消融放疗的I期TITE-CRM试验

Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial.
PubMed 文献 · Radiother Oncol · 2018-04-09

这项前瞻性I期试验纳入26例不可手术的非小细胞肺癌患者,在46 Gy同步放化疗后给予3次立体定向消融放疗补量,剂量从3×7 Gy递增至3×12 Gy,采用TITE-CRM方法进行剂量递增。结果显示补量至3×11 Gy水平出现1例食管瘘(伴局部复发),3×12 Gy水平出现1例咯血死亡,方案推荐的安全剂量为3×11 Gy。

要点

  • 同步放化疗后SABR补量的推荐安全剂量为3×11 Gy。
  • 3×12 Gy水平出现1例咯血死亡,3×11 Gy水平出现1例食管瘘伴局部复发。
  • 2年局部控制率70.3%,总生存率50.8%。

核心结论

  • 在不可手术非小细胞肺癌同步放化疗后给予立体定向消融放疗补量,本方案推荐的安全剂量为3×11 Gy。

研究设计与样本

  • 前瞻性I期试验纳入26例不可手术的非小细胞肺癌患者,采用时间-事件持续再评估方法(TITE-CRM)进行剂量递增。
  • SABR补量剂量范围为3×7 Gy至3×12 Gy,在46 Gy(每日2 Gy)同步放化疗后进行。

主要发现

  • 中位随访37.1个月(范围1.7-60.7个月),剂量水平1至6分别纳入3、4、3、3、9和4例患者。
  • 同步放化疗期间9例患者出现3级毒性。
  • 立体定向放疗后,3×11 Gy水平1例出现食管瘘(伴局部复发),3×12 Gy水平1例死于咯血。
  • 2年局部控制率、无局部区域复发生存率、无转移生存率和总生存率分别为70.3%、55.5%、44.5%和50.8%。

关键数值与推荐

  • 本方案推荐的安全补量剂量为3×11 Gy。
  • 剂量递增范围为3×7 Gy至3×12 Gy,同步放化疗剂量为46 Gy(每日2 Gy)。

临床怎么用

  • 对于不可手术的非小细胞肺癌,可在46 Gy同步放化疗后考虑3×11 Gy的SABR补量,但需注意食管瘘和咯血风险。

局限性

  • 本文为I期试验,样本量26例,主要目的是确定可行性和安全剂量,疗效数据需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Platinum based chemoradiotherapy is the standard of care for inoperable non-small cell lung cancer (NSCLC). With evidence that NSCLC can have a dose dependent response with stereotactic ablative radiotherapy (SABR), we hypothesize that a SABR boost on residual tumor treated with chemoradiotherapy could increase treatment efficacy. The purpose of this study was to determine feasibility of such an approach. MATERIAL AND METHODS: A prospective phase I trial was performed including 26 patients. Time-to-event continual reassessment method (TITE-CRM) was used for dose escalation which ranged from 3 × 7 to 3 × 12 Gy for the stereotactic boost, after 46 Gy (2 Gy per day) of chemoradiotherapy. RESULTS: Median follow-up was of 37.1 months (1.7-60.7), and 3, 4, 3, 3, 9 and 4 patients were included at the dose levels 1, 2, 3, 4, 5 and 6, respectively. During chemoradiotherapy, 9 patients experienced grade 3 toxicity. After stereotactic radiotherapy, 1 patient experienced an esophageal fistula (with local relapse) at the 3 × 11 Gy level, and 1 patient died from hemoptysis at the 3 × 12 Gy level. The 2-year rate of local control, locoregional free survival, metastasis-free survival, and overall survival was 70.3%, 55.5%, 44.5% and 50.8%, respectively. CONCLUSION: In the treatment of NSCLC with chemoradiotherapy followed by a stereotactic boost, the safe recommended dose in our protocol was a boost dose of 3 × 11 Gy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Doyen J, Poudenx M, Gal J, et al. Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial. Radiother Oncol. 2018. PMID: 29650404. doi:10.1016/j.radonc.2018.03.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。